The role of the visceral adiposity index in the assessment of metabolic syndrome of polycystic ovary syndrome patients: a new anthropometric index
- PMID: 38321350
- DOI: 10.1007/s00404-023-07328-7
The role of the visceral adiposity index in the assessment of metabolic syndrome of polycystic ovary syndrome patients: a new anthropometric index
Abstract
Purpose: Polycystic ovary syndrome (PCOS) is a common endocrine disorder often linked to metabolic syndrome (MS), raising the risk of cardiovascular disease and type II diabetes. Certain indicators, such as the lipid accumulation product (LAP) and homeostatic model assessment for insulin resistance (HOMA-IR), can predict MS in PCOS patients. This study aimed to assess the predictive power of the visceral adiposity index (VAI) in comparison to LAP and HOMA-IR as predictors of MS in PCOS patients.
Methods: In this cross-sectional observational study, data from 317 diagnosed PCOS women were analyzed. VAI, LAP, and HOMA-IR were computed as indexes. Participants were categorized into two groups for index accuracy comparison: PCOS patients with and without MS. The data were assessed using a ROC curve.
Results: Among PCOS women with MS, 92.3% had abnormal VAI results, 94.5% had abnormal LAP results, and only 50.5% had abnormal HOMA-IR results. Conversely, the majority of PCOS women without MS had normal HOMA-IR (64.6%). When comparing these indexes using the ROC curve, VAI displayed the highest accuracy, followed by LAP and HOMA-IR.
Conclusion: The VAI index proved to be a superior predictor of metabolic MS in PCOS women when compared to other indexes.
Keywords: Cardiovascular risks; Metabolic Syndrome (MS); Polycystic ovary syndrome (PCOS); Type II diabetes; Visceral adiposity index (VAI).
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Lipid Accumulation Product (LAP) and Visceral Adiposity Index (VAI) as Markers of Insulin Resistance and Metabolic Associated Disturbances in Young Argentine Women with Polycystic Ovary Syndrome.Horm Metab Res. 2017 Jan;49(1):23-29. doi: 10.1055/s-0042-113463. Epub 2016 Aug 29. Horm Metab Res. 2017. PMID: 27571188
-
Visceral and Dysfunctional Adiposity Indices as Predictors of Insulin Resistance and Metabolic Syndrome in Women with Polycystic Ovary Syndrome: A Cross-Sectional Study.Medicina (Kaunas). 2025 Feb 28;61(3):424. doi: 10.3390/medicina61030424. Medicina (Kaunas). 2025. PMID: 40142235 Free PMC article.
-
The impact of lipid accumulation product (LAP) and visceral adiposity index (VAI) on clinical, hormonal and metabolic parameters in lean women with polycystic ovary syndrome.Gynecol Endocrinol. 2019 Mar;35(3):233-236. doi: 10.1080/09513590.2018.1519794. Epub 2018 Oct 10. Gynecol Endocrinol. 2019. PMID: 30303693
-
Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.Nutr Res Rev. 2017 Jun;30(1):97-105. doi: 10.1017/S0954422416000287. Epub 2017 Feb 22. Nutr Res Rev. 2017. PMID: 28222828 Review.
-
Visceral adiposity index as a predictor of clinical severity and therapeutic outcome of PCOS.Gynecol Endocrinol. 2016;32(3):177-83. doi: 10.3109/09513590.2015.1111327. Epub 2015 Nov 20. Gynecol Endocrinol. 2016. PMID: 26502288 Review.
Cited by
-
Dissociation of plasma oxyntomodulin levels from anthropometric measures and metabolic markers in women with polycystic ovary syndrome.Arch Endocrinol Metab. 2025 Jun 18;69(3):e240451. doi: 10.20945/2359-4292-2024-0451. Arch Endocrinol Metab. 2025. PMID: 40532052 Free PMC article.
-
Association between visceral adiposity index and cancer risk in the UK Biobank cohort.Cancer. 2025 Jan 1;131(1):e35576. doi: 10.1002/cncr.35576. Epub 2024 Oct 3. Cancer. 2025. PMID: 39361532 Free PMC article.
References
-
- Amato MC, Magistro A, Gambino G, Vesco R, Giordano C (2015) Visceral adiposity index and DHEAS are useful markers of diabetes risk in women with polycystic ovary syndrome. Eur J Endocrinol 172(1):79–88. https://doi.org/10.1530/EJE-14-0600 - DOI - PubMed
-
- ESHRE Rotterdam ASRM-Sponsored (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47 - DOI
-
- Mousa A, Tay CT, Teede H (2023) Technical report for the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Monash University, Melbourne
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials